China's Second-largest CRO Seeks Initial Public Offering In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Shanghai-based ShangPharma hopes to capitalize on a growing wave of outsourcing by biopharmaceutical developers looking to reduce costs and spread risk in the wake of an R&D productivity slump.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
WuXi PharmaTech Set To Compete Globally Following OECD Certification Of New Drug Toxicology Lab In China
BEIJING - Armed with a new certification on good laboratory practice compliance from the Organization for Economic Cooperation and Development, WuXi PharmaTech's preclinical testing facility could be poised to battle the globe's giants in providing toxicology services for international players